Results 101 to 110 of about 958,101 (344)

Epidemiology of hepatitis C [PDF]

open access: yesEuropean Journal of Gastroenterology & Hepatology, 1996
In the United States, the annual number of newly acquired acute hepatitis C virus (HCV) infections has declined from an estimated 180,000 in the mid 1980s to an estimated 28,000 in 1995. Approximately 25% to 30% of these infections are clinically apparent cases that are sufficiently symptomatic to gain medical attention ...
openaire   +5 more sources

Antiviral Therapy for Hepatitis C Prophylaxis in Percutaneous Exposure and Acute Hepatitis C [PDF]

open access: yes, 2012
Incidence of percutaneous exposure to hepatitis C virus (HCV) is still quite high, particularly in medical staffs. Though not all will cause infection, but if acute HCV infection occurs, it usually develops into chronic hepatitis which finally causes ...
Kurniawan, J. (Juferdy)   +1 more
core   +1 more source

Genetic Engineering Methods in Primary T Cells

open access: yesAdvanced Therapeutics, EarlyView.
Primary T cells can be engineered to confer them with novel therapeutic functions, allowing them to treat a variety of conditions. Genetic engineering can be either stable or transient, aiming to either express or inhibit a target gene. This review discusses the various genetic engineering tools available as well as their characteristics and ...
Anthony Youssef, Hui‐Shan Li
wiley   +1 more source

Virtual screening for NS5B inhibitors of Hepatitis C virus [PDF]

open access: yes, 2012
Hepatitis C Virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at a risk of developing significant morbidity and mortality.
Achuthsankar S. Nair   +2 more
core   +2 more sources

Tryptophan Metabolite Indole‐3‐Aldehyde Induces AhR and c‐MYC Degradation to Promote Tumor Immunogenicity

open access: yesAdvanced Science, EarlyView.
Tryptophan metabolite Indole‐3‐aldehyde (I3A) downregulates cytosolic AhR and p‐ERK/c‐MYC proteins, together enhancing STAT3 phosphorylation and tumor immunogenicity. Overexpression of the Trp metabolic enzyme interleukin‐4‐induced gene‐1 (IL4I1) in tumor cells increases intracellular levels of I3A and enhances tumor immunogenicity.
Lei Cui   +19 more
wiley   +1 more source

Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b

open access: yesCell Reports, 2017
Summary: Secretory cells produce diverse cargoes, yet how they regulate concomitant secretory traffic remains insufficiently explored. Rab GTPases control intracellular vesicular transport.
Constantin N. Takacs   +11 more
doaj   +1 more source

Complete replication of hepatitis C virus in cell culture. [PDF]

open access: yes, 2005
Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced in cell culture, which has slowed research progress on this important human pathogen.
Burton, Dennis R   +10 more
core   +1 more source

Engineered RGD‐Treg‐Exos Targeted Delivery of miR‐218‐5p to Activate Mitophagy and Attenuate Podocyte Injury in Diabetic Kidney Disease

open access: yesAdvanced Science, EarlyView.
Tregs‐Exos deliver miR‐218‐5p to increase mitophagy in podocytes by inhibiting the TNC/TLR4/SRC/FUNDC1 pathway. RGD‐Treg‐Exos, engineered to express RGD peptides on the membrane surface, bind to integrins on the surface of podocytes and effectively target podocytes for the delivery of miR‐218‐5p, which increases mitophagy and reduces apoptosis in ...
Zhaochen Guo   +11 more
wiley   +1 more source

Hepatitis C [PDF]

open access: yesJournal of Midwifery & Women's Health, 2021
openaire   +2 more sources

Revealing Cell‐Free Mitochondrial DNA Breakage Patterns as Novel Biomarkers for Sepsis

open access: yesAdvanced Science, EarlyView.
Uncovering distinct plasma cfmtDNA breakage patterns opens new frontiers for early sepsis detection and prognosis. Unique cleavage hotspots in RNR2 and COX2 regions outperform traditional biomarkers, while mechanistic insights suggest bacterial endonuclease involvement.
Haitang Liao   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy